Latest News and Press Releases

AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances

AAVantgarde announces 2 presentations at ARVO 2025 annual meeting

AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa USH1B

AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024 annual meeting

AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081 for the Treatment of Usher Syndrome Type 1B Retinitis Pigmentosa

AAVantgarde Founder and Chief Scientific Officer, Professor Alberto Auricchio, is elected as President of the European Society of Gene and Cell Therapy

AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer

MILAN, Oct. 08, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector...

AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study

AAVantgarde appoints Dr. Jayashree Sahni as Chief Medical Officer